Research-based biopharma company providing innovative therapeutics for unmet medical needs
Orphan Biologics under the Orphan Drug Act; seek amendment to health-care reform legislation to enable continued rare-disease research under the Orphan Drug Act for biologics as part of follow-on biologics pathway by establishing an Orphan Delta for Orphan Biologics to incentivize research and development of Orphan Biologics to treat rare diseases and conditions.
HCR - Health Issues
2 - HOUSE OF REPRESENTATIVES 1 - SENATE
ENGEL & NOVITT, LLP
2401 Pennsylvania Avenue, N.W., Suite #310, Washington, DC, 20037-1730, US
JOHN M. ENGEL (N/A)
N/A